Streetbeat News

APGE

Apogee Therapeutics, Inc.

https://www.apogeetherapeutics.com

Industry

Biotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Open

44.14

Mkt cap

2.6B

Volume

686K

High

45.32

P/E Ratio

-18.31

52-wk high

72.29

Low

41.85

Div yield

N/A

52-wk low

22.11

Apogee Therapeutics' stock price has seen an increase following B of A Securities initiating coverage with a Buy rating.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 12:56 pm

B of A Securities has initiated coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and set a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 10:50 am

As of March 14, 2024, Molina Healthcare, Inc. (MOH), Apogee Therapeutics, Inc. (APGE), and CymaBay Therapeutics, Inc. (CBAY) are identified as overbought health care stocks with RSI values significantly above 70, indicating potential short-term performance concerns. MOH's RSI stands at 88.79, APGE's at 86.76, and CBAY's at 80.88, suggesting they may be due for a correction.

Portfolio Pulse from Avi Kapoor

March 14, 2024 | 12:57 pm

Apogee Therapeutics has announced an upsized underwritten public offering of 6,774,193 common shares at $62 per share, aiming to raise approximately $420 million. The offering is set to close on March 12, 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:52 am

Apogee Therapeutics' stock price is on the rise following an upgrade from Jefferies, which maintained a Buy rating and increased the price target from $37 to $75.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 7:33 pm

Jefferies analyst Akash Tewari has maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE) and increased the price target from $37 to $75.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:38 pm

Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company, has announced the commencement of a $350 million underwritten public offering of its common stock, with an option for underwriters to purchase an additional $52.5 million. The offering is subject to market conditions, and the securities are offered by Apogee. Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen, and Stifel are the joint book-running managers.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:30 pm

Apogee Therapeutics has filed for an offering of 6 million shares of its common stock. This move is aimed at raising capital, potentially for further research, development, and expansion of its operations.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:18 pm

U.S. stocks traded lower with the Dow Jones falling around 350 points. Energy shares rose by 1.3%, while information technology shares fell by 2.2%. Consolidated Communications Holdings Inc (CNSL) reported a narrower-than-expected Q4 loss but missed revenue expectations. Dave Inc. (DAVE) shares jumped 51% after reporting increased Q4 revenue. Airship AI Holdings, Inc. (AISP) surged 87% following a Department of Justice contract announcement. Apogee Therapeutics, Inc. (APGE) gained 51% after announcing positive trial results. Quoin Pharmaceuticals, Ltd. (QNRX) and ThredUp Inc. (TDUP) saw significant drops after announcing a public offering and reporting Q4 results, respectively.

Portfolio Pulse from Avi Kapoor

March 05, 2024 | 7:11 pm

Stifel analyst Akash Tewari has maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE) and increased the price target from $46 to $95.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 6:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.